Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Ibrutinib
As low as
CHF 90.00
In stock
Only %1 left
AG-CR1-3620-M0055 mgCHF 90.00
AG-CR1-3620-M02525 mgCHF 180.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | PCI-32765 |
| Product Type | Chemical |
| Properties | |
| Formula |
C25H24N6O2 |
| MW | 440.5 |
| CAS | 936563-96-1 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White solid. |
| Solubility | Soluble in DMSO. Slightly soluble in ethanol (1mg/ml). Insoluble in water. |
| InChi Key | XYFPWWZEPKGCCK-GOSISDBHSA-N |
| Smiles | NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)C1CCCN(C1)C(=O)C=C |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Safety Data Sheet |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
- Potent and highly selective Bruton's tyrosine kinase (BTK) inhibitor. Orally bioavailable and irreversible inhibitor of BTK (IC50 = 0.5 nM) with antineoplastic activity.
- Binds to and irreversibly inhibits BTK activity, preventing B cell activation and B cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK.
- Shown to inhibit autophosphorylation of BTK (IC50 = 11nM), phosphorylation of PLCγ (IC50 = 29nM), a substrate of BTK and phosphorylation of ERK (IC50 = 13nM).
Product-specific References
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy: L.A. Honigberg, et al.; PNAS 107, 13075 (2010)
- BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB: S.A. Rushworth, et al.; Cell Signal. 25, 106 (2013)
- In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1: H. Zhang, et al.; Br. J. Pharmacol. 171, 5845 (2014)
- Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase: M.S. Davids & J.R. Brown; Future Oncol. 10, 957 (2014) (Review)
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF